Publications by authors named "Jonathan Sackner-Bernstein"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

608

Total Likes

47

Extended Reach

14,804

Social Features

12
D
Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis.
Jonathan Sackner-Bernstein, David Kanter, Sanjay Kaul

PLoS One· June 2016

Videos about Article: user user user

3 42 9 5 18 2

View All Article and Social Media Activity
R
Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility?
Jonathan Sackner-Bernstein

J Neurol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transurethral Renal Pelvic Denervation: A Feasibility Trial in Patients with Uncontrolled Hypertension.
Dagmara Hering, David Nikoleishvili, Avtandil Imedadze, Gvantsa Dughashvili, Zurab Klimiashvili, Jonathan Sackner-Bernstein

Hypertension· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimates of Intracellular Dopamine in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Jonathan Sackner-Bernstein

J Parkinsons Dis· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval of Eteplirsen for Muscular Dystrophy.
Jonathan Sackner-Bernstein

JAMA· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of Hack-Resistant Diabetes Devices and Disclosure of Their Cyber Safety.
Jonathan Sackner-Bernstein

J Diabetes Sci Technol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is the greatest regulatory challenge in the translation of biomaterials to the clinic?
Glenn D Prestwich, Sangeeta Bhatia, Christopher K Breuer, Shannon L M Dahl, Chris Mason, Jonathan Sackner-Bernstein

Sci Transl Med· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
Christopher M O'Connor, Alan B Miller, John E A Blair, Marvin A Konstam, Patricia Wedge, Jonathan D Sackner-Bernstein

Am Heart J· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
James E Udelson, Susan J Pressler, Jonathan Sackner-Bernstein, Joseph Massaro, Paul Ordronneau

J Card Fail· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure.
Mathew S Maurer, Jonathan D Sackner-Bernstein, Lyna El-Khoury Rumbarger, Madeline Yushak, Donald L King

Circ Heart Fail· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nesiritide for acute decompensated heart failure: does the benefit justify the risk?
Jonathan Sackner-Bernstein, Keith D Aaronson

Curr Cardiol Rep· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.
Paul J Hauptman, Susan J Pressler, Jonathan Sackner-Bernstein, Paul Ordronneau, James E Udelson

Am J Cardiol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of death associated with nesiritide in patients with acutely decompensated heart failure.
Keith D Aaronson, Jonathan Sackner-Bernstein

JAMA· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy.
Jonathan Sackner-Bernstein

Clin Cardiol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nesiritide--not verified.
Jonathan Sackner-Bernstein, Keith D Aaronson

N Engl J Med· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure.
Jonathan D Sackner-Bernstein

Curr Cardiol Rep· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.
Jonathan D Sackner-Bernstein, Marcin Kowalski, Marshal Fox, Keith Aaronson

JAMA· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.
Jonathan D Sackner-Bernstein, Hal A Skopicki, Keith D Aaronson

Circulation· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical guidelines to optimize effectiveness of beta-blockade in patients postinfarction and in those with chronic heart failure.
Jonathan D Sackner-Bernstein

Am J Cardiol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racing away from bias.
Jonathan D Sackner-Bernstein, Hal A Skopicki

J Am Coll Cardiol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is the role of biventricular pacing the transplant candidate?
Jonathan Sackner-Bernstein, D Michael Farmer

Coron Artery Dis· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurohormonal antagonism in heart failure: what is the optimal strategy?
Jonathan D Sackner-Bernstein, David Hart

Mt Sinai J Med· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.
Thomas M Behr, Robert N Willette, Robert W Coatney, Marinela Berova, Christiane E Angermann, Jonathan D Sackner-Bernstein

J Hypertens· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing organ transplantation--fairly.
Jonathan D Sackner-Bernstein, Seth Godin

Transplantation· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline.
Gregg C Fonarow, William T Abraham, Mihai Gheorghiade, Christopher P Cannon, Jonathan D Sackner-Bernstein

Crit Pathw Cardiol· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis